Research map: Antibody–drug conjugates in solid tumors: Efficacy, challenges, and opportunities

Back to the article

Papers in this map

  1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene · Dennis J. Slamon · 1987 · 11847 citations · Cited by this paper
  2. Leveraging cDC1 biology and function for enhanced immunotherapy · 2026 · Related
  3. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer · Sunil Verma · 2012 · 3861 citations · Cited by this paper
  4. Aquaporin-1 sustains lymphangiogenic responses in hyperosmotic inflammatory microenvironments · 2026 · Related
  5. IgG Subclasses and Allotypes: From Structure to Effector Functions · Gestur Vidarsson · 2014 · 2746 citations · Cited by this paper
  6. CNOT3 supports ILC2 differentiation and function by destabilizing Tbx21 and Rorc transcripts · 2026 · Related
  7. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer · Shanu Modi · 2022 · 2707 citations · Cited by this paper
  8. Flawed translation triggers oncogenic B–T cell communication · 2026 · Related
  9. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer · Gϋnter von Minckwitz · 2018 · 2688 citations · Cited by this paper
  10. Identification of secondary microglial formation centers in the human fetal brain · 2026 · Related
  11. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer · Shanu Modi · 2019 · 2027 citations · Cited by this paper
  12. eIF3e-mediated translational checkpoint maintains immune tolerance and prevents lymphoid malignancy · 2026 · Related
  13. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients · Yoichi Nagata · 2004 · 1879 citations · Cited by this paper
  14. Emerging Antibody-Drug Conjugate Therapies and Targets for Metastatic Renal Cell Carcinoma · 2023 · Related
  15. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer · Aditya Bardia · 2021 · 1674 citations · Cited by this paper
  16. Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters · 2026 · Related
  17. Antibody drug conjugate: the “biological missile” for targeted cancer therapy · Zhiwen Fu · 2022 · 1638 citations · Cited by this paper
  18. A review of conjugation technologies for antibody drug conjugates · 2025 · Related
  19. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics · Joshua J. Rennick · 2021 · 1504 citations · Cited by this paper
  20. Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors · 2025 · Related
  21. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer · Kohei Shitara · 2020 · 1352 citations · Cited by this paper
  22. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer · Javier Cortés · 2022 · 1197 citations · Cited by this paper
  23. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 · Yusuke Ogitani · 2016 · 1193 citations · Cited by this paper
  24. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer · Thomas B. Powles · 2024 · 1079 citations · Cited by this paper
  25. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial · Funda Meric‐Bernstam · 2023 · 1061 citations · Cited by this paper
  26. Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy · Ravi V. J. Chari · 2014 · 929 citations · Cited by this paper
  27. Lysosome biology in autophagy · Willa Wen‐You Yim · 2020 · 836 citations · Cited by this paper
  28. Apoptosis and glutathione: beyond an antioxidant · Rodrigo Franco · 2009 · 757 citations · Cited by this paper
  29. Bystander killing effect of DS ‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity · Yusuke Ogitani · 2016 · 752 citations · Cited by this paper
  30. Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models · Pia M. Challita-Eid · 2016 · 738 citations · Cited by this paper
  31. Tissue Factor · Steven Philip Grover · 2018 · 676 citations · Cited by this paper
  32. Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies · Laurent Ducry · 2009 · 625 citations · Cited by this paper
  33. Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing · Hans K. Erickson · 2006 · 585 citations · Cited by this paper
  34. The Ins and Outs of Cathepsins: Physiological Function and Role in Disease Management · Tulasi Yadati · 2020 · 559 citations · Cited by this paper
  35. Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer · John M. Lambert · 2014 · 547 citations · Cited by this paper
  36. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer · Kathleen N. Moore · 2023 · 481 citations · Cited by this paper
  37. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial · Hope S. Rugo · 2023 · 476 citations · Cited by this paper
  38. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer · Aditya Bardia · 2024 · 465 citations · Cited by this paper
  39. Site-selective modification strategies in antibody–drug conjugates · Stephen J. Walsh · 2020 · 463 citations · Cited by this paper

Source: OpenAlex (CC0)